AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint

AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint

Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research annual meeting in Boston. The company said the therapy showed improvements in several measures of func

AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Tria

AstraZeneca releases Phase 3 HICKORY trial data for efzimfotase alfa in hypophosphatasia (HPP), showing key secondary improvements.

AZ makes case for hypophosphatasia drug after phase 3 miss

AstraZeneca has high sales expectations for HPP therapy efzimfotase alfa, but will the data support the broad label needed to unlock its potential?

AstraZeneca reports HICKORY Phase III efzimfotase alfa results in hypophosphatasia, with primary endpoint not statistically significant

Week-25 walking distance improved numerically by 17.05 metres versus placebo, while fatigue and selected subgroup outcomes showed nominal benefits IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca announced Phase III HICKORY findings for investigational efzimfotase alfa in 124 treatment-naïve adolescents and adults with hypophosphatasia. … Read the full press release →